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ABSTRACT
Low circulating levels of vitamin D were associated with decreased muscle 
strength and physical performance. Along this line, the present study was aimed 
to investigate: i) the therapeutic potential of vitamin D in cancer-induced muscle 
wasting; ii) the mechanisms by which vitamin D affects muscle phenotype in tumor-
bearing animals.
Rats bearing the AH130 hepatoma showed decreased circulating vitamin D 
compared to control rats, while muscle vitamin D receptor (VDR) mRNA was up-
regulated. Both circulating vitamin D and muscle VDR expression increased after vitamin 
D administration, without exerting appreciable effects on body weight and muscle mass.
The effects of vitamin D on muscle cells were studied in C2C12 myocytes. Vitamin 
D-treated myoblasts did not differentiate properly, fusing only partially and forming 
multinucleated structures with aberrant shape and low myosin heavy chain content. 
Vitamin D treatment resulted in VDR overexpression and myogenin down-regulation. 
Silencing VDR expression in C2C12 cultures abrogated the inhibition of differentiation 
exerted by vitamin D treatment.
These data suggest that VDR overexpression in tumor-bearing animals 
contributes to muscle wasting by impairing muscle regenerative program. In this 
regard, attention should be paid when considering vitamin D supplementation to 
patients affected by chronic pathologies where muscle regeneration may be involved.
INTRODUCTION
Cachexia is a comorbidity of cancer [1] 
characterized by progressive loss of body weight as well 
as of skeletal muscle and adipose tissue mass. More 
than 50% of all cancer patients develop cachexia. This 
percentage increases up to 86% during the last 2 weeks of 
life and about 20% of all cancer deaths can be attributable 
to cachexia. Moreover, cachexia impairs quality of life, 
as well as tolerance and response to anti-neoplastic 
treatments (reviewed in [2]).
Anorexia, inflammation and perturbations of 
hormonal and metabolic homeostasis significantly 
contribute to the onset and progression of cachexia. In this 
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regard insulin, angiotensin, leptin and myostatin, together 
with numerous cytokines, including IL6, IL1 and TNFα 
have been shown to play a role [2, 3].
Skeletal muscle wasting is among the most 
important cilnical features of cancer cachexia. It mainly 
derives from the activation of a protein hypercatabolic 
response that involves different proteolytic systems, in 
particular the ubiquitin-proteasome-dependent pathway 
[4] and autophagy However, other mechanisms have also 
been suggested to contribute to muscle depletion, such 
as down-regulation of protein synthesis (see [2]) and 
impaired myogenic response [5, 6].
Vitamin (Vit) D3, the precursor of biologically 
active VitD, is a pleiotropic hormone synthesized 
mainly in the skin via a UV-dependent reaction. VitD3 
is then transported to the liver where it is hydroxylated 
at the C-25 position to produce 25(OH)-VitD, the major 
circulating form of this hormone. In order to become 
active, 25(OH)-VitD must be hydroxylated in the C-1 
position, producing 1,25(OH)-VitD (hereafter referred to 
as VitD). This enzymatic reaction takes place mainly in the 
kidney, although other cells/tissues express the CYP27B1 
enzyme required for hydroxylation [7]. VitD circulates in 
the blood bound to vitamin D-binding proteins, reaching 
its target tissues to exert endocrine actions. These latter are 
mediated by the vitamin D receptor (VDR), a member of 
the nuclear receptor family of transcription factors, which 
is expressed in different tissues (reviewed in [8]). VDR 
knock-out mice show the full phenotype of severe vitamin 
D deficiency, indicating that VDR is the major mediator 
of VitD action [9]. Upon binding to VitD, VDR forms a 
heterodimer with the retinoid-X receptor and regulates 
the expression of genes whose promoters contain specific 
DNA sequences known as VDR responsive elements 
(VDRE). A number of coactivators and corepressors are 
involved in this transcriptional regulation, providing 
context, tissue and target gene specificity [8]. However, 
some actions of VitD have been shown to be more 
immediate than those described above, and have been 
suggested to depend on engagement of a membrane 
associated VDR [10].
The classical and best known functions of VitD 
involve the regulation of calcium and phosphate 
metabolism, mainly acting on bone tissue, intestine and 
kidneys [11]. More recently, VitD has been demonstrated 
to play a role in several physiological and pathological 
processes, such as immune response and cancer 
development [8].
VitD deficiency has been shown to cause 
abnormalities in skeletal muscle, such as reduced 
actomyosin content, decrease in mitochondrial Ca2+ levels, 
reduced Ca2+ uptake in the sarcoplasmic reticulum and 
low creatine kinase serum levels [12]. VitD deficiency 
is common in aged individuals, and has been proposed 
as an independent indicator of frailty and mortality [13]. 
Recently, VitD deficiency has been shown to result in 
muscle wasting with increased protein breakdown due to 
hyperactivation of the ubiquitin-proteasome pathway [14]. 
Consistent with a protective role of VitD in muscle, VitD 
supplementation in elderly patients has been shown to 
improve skeletal muscle functions, such as increased lower 
limb muscle strength [15] and reduction in the relative risk 
of falls [16]. Nevertheless, a number of studies have failed 
to demonstrate an effect of VitD on physical performance 
[17, 18], a matter that is still controversial [19].
VitD effects on muscle cells are long known [20], 
and several observational studies have been performed on 
the role of VitD on skeletal muscle. VDR knock-out mice 
have provided evidences for a direct role of this steroid 
receptor in the skeletal muscle. Endo and coworkers 
(2003) have demonstrated that myofibers in VDR-null 
mutant mice are smaller than in wild type mice. Moreover, 
they showed that skeletal muscles from 3 weeks old mice 
lacking VDR display an abnormally elevated expression 
of myogenic factors such as Myogenin, Myf5 and E2A, as 
well as increased expression of embryonic and neonatal 
myosin heavy chain (MyHC; [21]). Taken together, these 
data suggest that VDR is an important regulator of skeletal 
muscle development and differentiation.
Despite evidence demonstrating that VitD acts 
on the skeletal muscle, the effectiveness of VitD 
administration in pathological conditions characterized 
by muscle atrophy has not been assessed. For this reason, 
the present study was designed to investigate: i) the 
role of VitD in the pathogenesis of cancer cachexia; ii) 
the possibility to use VitD treatment to prevent muscle 
wasting in an experimental model of cancer cachexia 
(rats bearing the AH130 Yoshida ascites hepatoma); iii) 
the mechanisms by which vitamin D might affect muscle 
phenotype in tumor-bearing animals. The results obtained 
show that, while VitD does not significantly improve 
cachexia, it does affect myogenesis.
RESULTS
VitD administration did not prevent cachexia in 
the AH130 hosts
Rats bearing the AH130 hepatoma represent a well 
characterized model for the study of cancer cachexia, 
showing a progressive loss of body weight that parallels 
tumor growth [22]. Body weight loss in the AH130 bearers 
is associated with severe depletion of skeletal muscle mass 
(Figure 1A) and with significant reduction of VitD plasma 
levels below control values (Figure 1B). Low circulating 
VitD, is paralleled by a significant increase of VDR mRNA 
in the skeletal muscle of the AH130 hosts (Figure 1C).
The administration of VitD3 (80 IU/kg, daily 
intragastrical administration, starting the day of 
transplantation) increases 25(OH)-VitD circulating levels 
(about 35% above baseline) in both controls and AH130 
hosts (Figure 1B). However, no appreciable effects on 
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tumor mass (data not shown), final body weight (FBW), 
gastrocnemius and tibialis muscle mass (GSN and TIB 
respectively) can be observed in treated vs untreated 
animals (Figure 1A). Consistent with previous in vitro and 
in vivo observations [23], VitD3 supplementation induced 
an increase above baseline of VDR mRNA expression in 
the tibialis muscle of control animals (confirming data 
by Girgis et al [24]) and further exacerbated the increase 
occurring in the AH130 hosts (Figure 1C).
Muscle VDR overexpression was observed in 
tumor hosts
To ascertain that VDR overexpression in the skeletal 
muscle is not a peculiar feature of the AH130-bearing rats, 
VDR levels were assessed also in mice transplanted with 
the Lewis lung carcinoma (LLC) or with the Colon 26 
carcinoma (C26), both being able to induce cachexia in 
the host mouse [6, 25].
Mice injected with LLC cells show a significant 
decrease in body weight and skeletal muscle mass, as 
reported in Figure 2A. Although 25(OH)-VitD plasma 
levels were not significantly different between controls 
and tumor-bearing mice (Figure 2B), VDR protein 
expression was increased in the skeletal muscle of the 
latter (Figure 2B, 2C).
C26 tumor growth is associated with a marked 
loss of body weight, as well as of both gastrocnemius 
and tibialis muscle mass (Figure 2D). Both 25(OH)-VitD 
levels and VDR expression were increased in the C26 
Figure 1: Effects of VitD3 administration to rats bearing the AH130 hepatoma. A. Body weight changes, gastrocnemius 
and tibialis muscle weight in controls and tumor-bearing rats either untreated or receiving VitD3. B. VitD plasma levels in untreated and 
VitD3-treated rats. C. VDR mRNA expression levels in the tibialis muscle of untreated and VitD3-treated animals. Data (means±SEM) 
are expressed as fold change (control rats: n=6, tumor-bearing rats: n=8). Significance of the differences: *p< 0.05 vs control; #p< 0.05 vs 
AH130.
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bearers with respect to control mice (Figures 2E, 2F). 
25(OH)-VitD circulating levels were markedly lower in 
control Balb/c mice than in control C57BL/6J animals, 
conforming to previous data [26]. The administration 
of VitD3 to the C26 hosts produced results comparable 
to those reported in rats bearing the AH-130 hepatoma 
(Supplementary Figure 1).
Finally, VDR mRNA expression was also increased 
in skeletal muscle biopsies of cancer patients with respect 
to those of control subjects (Supplementary Figure 2).
Muscle VDR levels regulate myogenic 
differentiation
The VDR signaling pathway has been linked 
to defects in skeletal muscle development [21]. To 
investigate this point, the effects of VitD treatment 
were studied in vitro on C2C12 myocyte cultures. VitD 
addition to the culture medium slowed C2C12 myoblast 
proliferation in a dose- and VDR-dependent manner 
(data not shown), confirming previous observations [24, 
27]. Moreover, attempts to produce VDR overexpressing 
C2C12 myoblasts by gene transfection were revealed to 
be unsuccessful, suggesting that high VDR levels might 
be toxic, in myoblasts at least, lowering proliferation rates 
and eventually leading to cell death (data not shown).
To test if VitD could affect myogenic differentiation, 
C2C12 myoblasts were grown to confluence and then 
induced to differentiate in the appropriate medium, 
with or without 10 nM 1.25-OH2-vitD for 4 days. As 
demonstrated by immunofluorescence for MyHC (Figure 
3A), control myoblasts were able to fuse together 
and to form myotubes with the canonical elongated 
structure, while VitD treated cells only partially fused 
(avarage number of nuclei/myotube: C=6.26±1.99, 
VitD=3.33±1.56, p<0.05, n=200. Total number of nuclei: 
Figure 2: VitD levels and VDR expression in mice bearing the LLC or the C26 tumor. A, D. Final body weight (FBW), 
gastrocnemius (GSN) and tibialis (TIB) mass in controls (n=5) and tumor-bearing mice (n=7). B, E. Circulating VitD and VDR protein 
expression levels in GSN muscle. C, F. Representative WB analysis of VDR expression in the gastrocnemius (anti-VDR antibody, clone 
D6, Santa Cruz Biotechnology). Data are means±SD. Significance of the differences: *p< 0.05 vs C.
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C=83.66±13.01, VitD=58.66±14.67, p=0.09, n=3) and 
give rise to multinucleated structures with aberrant shape 
and low MyHC content (Figure 3A and Supplementary 
Figure 3A). Western blotting analysis showed a rapid 
decline of VDR levels as differentiation progressed; such 
reduction is paralleled by increased levels of myogenin, 
one of the markers of myogenic differentiation (Figure 
3B, Supplementary Figure 3B). When differentiation 
was induced in the presence of VitD, the levels of 
myogenic regulatory factors such as Pax7 and myogenin 
were significantly reduced, at both 2 and 4 days after 
shifting to differentiation medium, while the expression 
of MyoD was not different from controls (Figure 3C, 
Supplementary Figure 3C). At the same time, in parallel 
to myogenin reduction, VDR was overexpressed at both 
mRNA (Supplementary Figure 3D) and protein level 
(Figure 4A), in a negatively correlated manner (r2=0.89, 
p-value = 0.0031).
To ascertain if VitD treatment could also affect 
mature myotubes, C2C12 myoblasts were differentiated 
for 4 days in regular differentiation medium and then 
treated with for 48 h with VitD (10-100 nM) or with 
IL-6, as a positive control of fiber shrinkage [28]. 
The results show that only 100 nM VitD significantly 
decreased myotube size (Figure 4B), while the number 
of nuclei per myotube was significantly reduced by both 
VitD concentrations (Figure 4B). Interestingly, although 
IL-6 treatment was comparable to 100 nM VitD as for 
myotube shrinkage, it did not affect the number of nuclei 
per myotube (Figure 4B), suggesting that two different 
mechanisms are responsible for VitD and IL-6-induced 
decrease of myotube size. Finally, VitD, but not IL-6, 
treatment of C2C12 myotubes markedly increased VDR 
expression (Figure 4C).
The observation reported above that myogenin and 
VDR expression are negatively correlated suggested the 
occurrence of a direct transcriptional regulator activity 
of VDR. To investigate this point, the promoter region 
of the mouse myogenin gene was analyzed in silico for 
the presence of putative VDRE. Figure 5A shows the 
Figure 3: Effects of VitD on C2C12 myoblast differentiation. A. Immunostaining of control or VitD-treated C2C12 cells after 
4 days of differentiation (Red: MyHC, Blue: nuclei). B. Expression levels of VDR (black line) and myogenin (grey line) during C2C12 
myoblast differentiation in the absence of VitD treatment, as measured by western blotting analysis (Santa Cruz Biotechnology: anti-VDR 
antibody, clone D6; anti-myogenin antibody, clone F5D). C. Protein expression levels of some myogenic regulatory factors in control or 
VitD-stimulated C2C12 cells at day 2 and 4 of differentiation (Santa Cruz Biotechnology: anti-myogenin antibody, clone F5D, anti-MyoD 
antibody, clone M318; Developmental Studies Hybridoma Bank, University of Iowa: anti-Pax7 antibody). Data (means±SD) are expressed 
as % of controls. Significance of the differences: ***p<0.001, **p<0.01, *p<0.05 vs C, 3 independent experiments.
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presence of 15 predicted VDR responsive elements in 
the 10kb upstream myogenin transcription start, six of 
which placed in the last 5kb upstream the coding region. 
Chromatin immunoprecipitation was performed to validate 
the in silico analysis. The results demonstrate that three 
among the putative binding sites exhibited an enrichment 
after immunoprecipitation with anti-VDR antibody, 
demonstrating a direct interaction of VDR with the 
myogenin promoter (Probes 1, 3, 7; Figure 5B).
VDR silencing restores C2C12 myoblast 
differentiation
To test the relevance of VDR to myogenesis, its 
expression was silenced by means of lentivirus-delivered 
specific shRNA. In this condition (shVDR), C2C12 
cells were no longer sensitive to VitD treatment and 
differentiated normally into mature myotubes (Figure 6A), 
as also indicated by the number of nuclei/myotube (Figure 
6C). Figure 6B shows that VDR silencing was robust (-83% 
in shVDR cells compared to shC) and that the marked 
reduction of both myogenin and MyHC expression induced 
by VitD treatment in ShC infected cells was not detectable 
in shVDR cultures (Figure 6C). Intriguingly, untreated 
ShVDR cultures expressed more myogenin and MyHC 
than untreated ShC cells (Figure 6B, 6C), suggesting that 
the lack of VDR enhanced myogenic differentiation even 
in basal conditions. When shVDR cells were stimulated 
with 10 nM VitD, the expression levels of both VDR and 
myogenin were at least as high as in ShC untreated cells.
VitD administration impairs muscle regeneration 
in vivo
To test whether the anti-differentiation effects 
mediated by VitD and VDR in vitro occur also in vivo, 
Figure 4: Effects of VitD on VDR and myogenin expression on C2C12 differentiating myoblasts and on myotubes. 
A. Protein expression levels of VDR and myogenin in control or VitD-stimulated C2C12 cells at day 4 of differentiation (Santa Cruz 
Biotechnology: anti-VDR antibody, clone D6, anti-myogenin antibody, clone F5D); B. Average myotube diameter and average number of 
nuclei/myotube in C2C12 cultures treated with control medium or with medium containing: 100ng/ml IL6, 10nM or 100nM VitD (bars 
show the average of three independent experiments, n=100 for each condition); C. Western blotting analysis of representative samples 
showing VDR expression (Santa Cruz Biotechnology: anti-VDR antibody, clone D6). Data are means ± SD. Significance of the differences: 
*p< 0.05 vs C, 3 independent experiments.
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Figure 5: VDR is recruited at regulatory regions of the myogenin gene after VitD exposition. A. Putative VDR binding 
sites in the promoter region of the Myogenin gene (6.5 Kbp), as predicted by LASAGNA-Search web tool, and schematic representation 
of the Myogenin promoter region showing putative binding sites for VDR; B. ChIP assay (representative pattern) was performed with 
chromatin extracted from C2C12 myoblasts treated or untreated with VitD, using normal rabbit IgG and an anti-VDR antibody. β-globin 
and cytochrome c promoter regions were amplified as negative and positive controls, respectively.
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VitD3 (80 IU/kg/day) was administered to animals in 
which muscle injury has been induced by BaCl2 injection 
in the tibialis anterior muscle. As described in the 
literature, BaCl2 causes an extensive muscle injury and 
the subsequent regeneration involves about 90% of muscle 
fibers [29]. In untreated mice, total fiber CSA as well as 
the number of fiber with central nuclei, evaluated 15 days 
after damage, were not significantly different between 
injured and uninjured muscles, suggesting that complete 
regeneration had already occurred (Figures 7A, 7C). By 
contrast, and consistent with the in vitro results, in the 
damaged muscle, the CSA of VitD3-treated animals was 
decreased, while the number of fibers with central nuclei 
was higher than in the controlateral uninjured one (Figures 
7A, 7C). In VitD3-supplemented mice VDR expression 
was markedly increased in the uninjured muscle, while 
it remained comparable to vehicle-treated animals in the 
regenerating one (Figure 7B and 7D). The expression 
level of myogenin and Pax7 were consistent with the 
impaired/delayed regeneration (Figure 7D). Finally, VitD3 
administration proved unable to improve muscle wasting 
also in experimental arthritis (Supplementary Figure 
4), a condition previously shown to be associated with 
enhanced muscle regeneration [30].
DISCUSSION
The present study is the first to investigate the 
involvement of VitD in the pathogenesis of cancer 
cachexia. Low VitD levels are a frequent feature in 
advanced cancer patients with cachexia and fatigue [31], 
while high serum VitD has been associated with low 
mortality in colorectal cancer patients [32]. However, 
data reported in the present study demonstrate that, 
Figure 6: Effects of VitD treatment on VDR-silenced C2C12 cells. A. Immunostaining of C2C12 cells after 4 days of differentiation 
(Red: MyHC, Blue: nuclei). B. Protein expression levels of VDR, MyHC and myogenin at day 4 of differentiation. Data (means±SD) are 
expressed as relative change. C. number of nuclei/myofiber. D. representative western blotting pattern of MyHC, myogenin and VDR 
expression (Santa Cruz Biotechnology: anti-VDR antibody, clone D6, anti-myogenin antibody, clone F5D; Sigma: anti MyHC antibody, 
clone MY32). Significance of the differences: *p<0.05 vs ShC, 2 independent experiments.
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depending on the experimental model of cancer cachexia 
chosen, circulating VitD levels may be reduced (AH130 
hosts), unchanged (LLC hosts) or increased (C26 hosts) 
compared to control values. Irrespective of circulating 
VitD, however, the presence of the tumor was always 
associated with up-regulation of muscle VDR expression. 
This in vivo observation, coupled with the results obtained 
in vitro, suggests that VDR might play a role in the onset 
and/or progression of cachexia.
Quite recent observations show that VitD 
supplementation in patients with non-metastatic HER2+ 
breast cancer treated with trastuzumab is associated with 
improved disease-free survival and with a tendency to 
increase body mass index [33]. Along this line, to assess 
if VitD supplementation could affect cancer cachexia, 
rats bearing the AH130 tumor, characterized by low 
VitD plasma levels, were treated with this hormone. 
The results show that body weight and muscle mass 
did not appreciably change in VitD-treated vs untreated 
tumor hosts, although VitD plasma levels in the former 
were nearly restored to control values. Of interest, in 
the AH130 hosts treated with VitD, muscle VDR levels 
were higher than those detected in the untreated tumor-
bearing rats, likely in view of the restoration of normal 
circulating vitamin levels. In this regard, it is well known 
that VitD positively regulates the expression of its main 
receptor both in vivo and in vitro [34, 35]. The other 
way round, the present study shows that increased VDR 
levels in the muscle of tumor-bearing animals seems a 
constant finding, irrespective of changes in circulating 
VitD levels. On the whole, these observations suggest 
that: i) a direct link between VitD plasma levels and the 
outcome of cancer cachexia is lacking; and ii) a ligand-
independent dysregulation of VDR signaling pathway 
could be involved in the pathogenesis of cancer-induced 
muscle wasting. In this regard, in certain conditions VDR 
Figure 7: Effects of VitD administration during muscle regeneration. A. Histological pattern of regenerating and non 
regenerating muscles in VitD3-treated (n = 6) and untreated mice (n = 6). For experimental details see Materials and Methods. B. VDR 
expression in regenerating and non regenerating muscles in the presence or in the absence of VitD3 treatment (Santa Cruz Biotechnology: 
anti-VDR antibody, clone D6). Data (means±SD) are expressed as relative change. Significance of the differences: *p< 0.05 vs C. C. Average 
myofiber CSA of controls (white bars) or regenerating (black bars) muscles 15 days after BaCl2 injection; 400 myofibers (regenerating or 
not)/condition have been counted. D. Representative samples showing VDR, Pax7 and myogenin expression (Santa Cruz Biotechnology: 
anti-VDR antibody, clone D6, anti-myogenin antibody, clone F5D; Developmental Studies Hybridoma Bank, University of Iowa: anti-Pax7 
antibody).
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has been proposed to act independently of VitD, although 
it still requires functional VitD responsive elements as 
well as an intact VDR DNA binding domain; the effects 
deriving from such action are thus indistinguishable 
from VitD-dependent transactivation [36]. On this line, 
VDR up-regulation in the skeletal muscle of tumor hosts 
could be considered per se as a condition sufficient for its 
transcriptional activity. Consistent with such a mechanism, 
a VitD-independent, toll-like receptor (TLR)2-dependent 
VDR hyperactivation has been proposed to contribute to 
the regulation of innate immune response [37].
The observation that VDR is overexpressed in the 
skeletal muscle of tumor-bearing animals suggests that the 
VitD/VDR-dependent signaling pathway might contribute 
to cancer-induced muscle wasting, despite the lack of 
effect of VitD supplementation. In this regard, VDR 
relevance to skeletal muscle biology has been previously 
described. As an example, Endo and coworkers reported 
that VDR knock-out mice develop muscles smaller than 
those of wild-type animals, with high expression levels 
of myogenic regulatory factors (MRF) such as Myogenin, 
Myf5 and E2A. Moreover, the authors showed that 
MRF expression in myoblast cultures is decreased by 
VitD treatment. An opposite view is reported by a study 
showing that MRF expression is reduced in VitD deficient 
rats [14].
The results obtained in the present study on C2C12 
and primary myoblasts clearly show that VitD treatment 
impairs their differentiation into mature myotubes, likely 
due to the modulation of both VDR (increased) and 
myogenin (decreased) expression. In this regard, these 
observations are consistent with recent data by Girgis 
and coworkers showing that VitD inhibits myotube 
formation in C2C12 cultures and that the few formed 
myotubes appeared bigger than those obtained in control 
C2C12 myocytes. The authors ascribed this latter effect 
to modulations of the myostatin-dependent pathway. No 
changes in myotube size were detected in the present study, 
however; the different experimental period (10 days in 
Girgis et al., 6 days in the present study) could account for 
such a discrepancy. The inhibition of myotube formation 
induced by vitD suggests an impairment of myogenesis. 
Consistent with this hypothesis, muscle regeneration 
after BaCl2-induced damage was altered in VitD-treated 
mice. The relevance of VDR to myogenic impairment 
in VitD-treated cells is demonstrated by the observation 
that normal differentiation was restored when VDR 
expression was silenced. Of interest, also in the absence 
of VitD stimulation, myogenin levels were higher in VDR-
silenced than in wild-type C2C12 cells, strengthening 
the hypothesis of a ligand-independent, VDR-mediated, 
negative regulation of myogenin transcription. Finally, 
the presence of several VDRE in the promoter region of 
the myogenin gene and the demonstration that VDR can 
directly bind the myogenin promoter support the proposed 
mechanism of regulation.
VDR expression in C2C12 cells is high at 
the beginning of the differentiation process and is 
progressively reduced until the cells complete their 
maturation into myotubes. This observation is consistent 
with previous data reported in the literature, showing 
that mean intracellular VDR content is higher in 
undifferentiated than in differentiated cells [35, 38]. 
Moreover, VDR expression is sustained in myoblasts 
of different origins as well as in the developing skeletal 
muscle [21, 39, 40]. By contrast, VDR expression in 
the adult muscle or in differentiated myotubes is always 
reported as very low or even absent [41], although the 
results shown in the present study demonstrate that it 
can be stimulated by VitD treatment, while not by the 
proinflammatory cytokine IL-6. While the atrophy-
inducing properties of IL-6 are well described, little is 
known about the possibility that VitD, likely through VDR, 
can stimulate myonuclei loss and/or MyHC degradation in 
differentiated myotubes. In this regard, however, the data 
shown in the present study are more likely representative 
of an inhibition of still ongoing myonuclei accretion. 
Indeed, C2C12 cultures are not completely differentiated 
after 4 days in differentiation medium (see Figure 3A). 
In addition, the suggestion that VitD does not stimulate 
protein degradation is supported by a previous report 
showing that protein synthesis induced by leucine and 
insulin in C2C12 myotubes is enhanced in the presence of 
10 nM calcitriol [42].
Taken together, these considerations highlight 
that VDR-dependent signaling pathway is likely to 
participate in the regulation of the first phases of myogenic 
differentiation in vitro and of skeletal muscle development 
and regeneration in vivo. In this regard, VDR down-
regulation may represent a condition required to achieve 
complete myogenic differentiation. Such a hypothesis 
is supported by the results in this study showing that 
animals administered VitD display an impaired muscle 
regeneration that is associated with a tendency to increase 
VDR expression. These results are in agreement with 
a very recent study showing that a supraphysiological 
dose of VitD injected into damaged muscle (days 4-7 
after BaCl2) delays the regenerative response [43]. 
The experimental setting shown in the present study, 
however, is quite different: the animals received VitD3, 
the administration route was intragastric, and treatment 
started the day of injury to finish the day before sacrifice.
An altered myogenic potential has been shown 
to contribute to cancer-induced muscle wasting [5, 6]. 
Activation of the MAPK/ERK pathway plays a role in this 
regard, contributing to keep Pax7+ cells from proceeding 
along differentiation, leading to their accumulation into the 
skeletal muscle [6]. The results shown in the present study 
suggest that also VDR overexpression could contribute to 
the impaired myogenesis observed in tumor hosts, mainly 
by altering the expression of myogenic factors involved 
in the differentiation program, such as myogenin [6]. 
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Interestingly, an interaction between ERK and VDR 
signaling pathways has previously been proposed: in MG-
63 (human osteoblastic osteosarcoma cell line) and HeLa 
(human cervical carcinoma cell line) cells, ERK activation 
leads to increased VDR transcriptional activity through 
overexpression of its coreceptor RXR gamma [44]. In this 
regard, ERK activation occurring in the skeletal muscle 
of cachectic tumor-bearing animals could be responsible 
for the establishment of a ‘VDR-prone’ environment, 
resulting in enhanced VDR-dependent signaling.
It is also worth citing that a relationship between 
VDR activation and skeletal muscle disorders has 
already been reported. The FokI polymorphism of VDR 
gene is a T/C transition in the second exon, resulting 
in a truncated protein (424aa instead of 427aa) with 
enhanced transactivation capacity [45]. Two studies in 
humans suggest that FokI polymorphism is associated 
with decreased skeletal muscle mass and strength. 
In particular, Roth and coworkers showed that FokI 
homozygous men display a low fat-free muscle mass and 
a risk of sarcopenia 2.17-fold higher than controls [46]. 
The other study demonstrates that homozygosity for the 
FokI polymorphism is associated with reduced quadriceps 
strength compared with heterozygosity or control subjects 
[47]. Finally, a recent study on cancer patients shows a 
correlation between the presence of specific VDR BsmI 
and TaqI alleles and CRP plasma levels, one marker of 
cancer cachexia [48]. In particular, the fact that VDR 
b and T alleles are more frequent in cachectic cancer 
patients with elevated CRP levels leads to the conclusion 
that this may represent an early clinical predictor for 
more aggressive forms of cachexia [49]. Intriguingly, the 
VDR bT genotype has been previously demonstrated to 
be associated with high expression levels of both VDR 
mRNA and protein [45, 50-52].
In conclusion, the present study suggests that VDR 
overexpression in animal models of cancer cachexia is 
likely contributing to skeletal muscle wasting through 
an impairment of the muscle regenerative program. An 
important limitation of the present study is the lack of a 
vitamin D-depleted control. Indeed, most of the clinical 
trials reported in the literature describe the effects of 
vitamin D supplementation in a context of vitamin D 
deficiency, while at least in part the present data reflect 
the effects of supraphysiological vitamin D levels. Another 
point is that vitamin D-induced VDR overexpression in 
the AH130 hosts does not worsen muscle wasting, in 
some way opposing to the potential involvement of VDR 
in causing cancer-induced muscle depletion. However, 
muscle weight loss in the AH-130 hosts is rather severe, 
and the possibility that it cannot be further exacerbated 
should be taken into account.
On the basis of the results shown in the present 
study we can then postulate that a note of caution should 
be made when considering VitD supplementation in 
patients affected by cancer cachexia or any other condition 
of skeletal muscle atrophy where a regenerative process 
might be involved. In this regard, too much circulating 
VitD may cause a further increase in the expression levels 
of VDR that could decrease the regenerative potential 
of skeletal muscle precursor cells. Along this line, the 
decrease in VitD circulating levels observed in the AH130 
hosts as well as in cancer patients [31] could represent 
a compensatory mechanism aimed at counteracting 
the increased VDR expression in the skeletal muscle. 
However, another possibility is that VitD plasma levels 
could be modulated independently from muscle VDR, for 
example by modulations of VitD-binding proteins. Finally, 
our in vitro experiments suggest that VDR is likely to 
play a fundamental role during myoblast differentiation, 
regulating and timing the expression of important 
myogenic factors, such as myogenin.
MATERIALS AND METHODS
Reagents
All reagents supplied by Sigma-Aldrich (St. Louis, 
MO, USA), unless differently specified.
In vivo experiments
Experimental animals were cared for in compliance 
with the Italian Ministry of Health Guidelines and the 
Policy on Humane Care and Use of Laboratory Animals 
(NIH, 1996). The experimental protocol was approved 
by the Bioethical Committee of the University of Torino 
(Torino, Italy). Male Wistar rats weighing approximately 
150 g, Balb-c and C57/BL6 mice weighing approximately 
20 g were obtained from Charles River (Calco, Italy) 
and were maintained on a regular dark-light cycle 
(light from 8 a.m. to 8 p.m.), with free access to food 
and water during the whole experimental period. Rats 
were injected intraperitoneally with 108 AH130 Yoshida 
ascites hepatoma cells [a gift many years ago from 
Prof. Ugo Del Monte (University of Milano, Milano, 
Italy) and maintained in our laboratory by weekly i.p. 
transplantation], whereas tumor-bearing mice (n= 8) were 
subcutaneously inoculated between the shoulder blades 
with 5 × 105 Colon 26 carcinoma cells [a gift from Prof. 
Mario P. Colombo (Istituto di Ricovero e Cura a Carattere 
Scientifico National Cancer Institute, Milano, Italy)] 
or with 5 × 105 Lewis Lung Carcinoma cells (ATCC, 
Manassas, VA). C26 and LLC cells were expanded to 
50,000/cm2 in vitro in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine 
serum, 100 U/mL penicillin, 100 μg/mL streptomycin, 
100 μg/mL sodium pyruvate, and 2 mmol/L L-glutamine. 
Cells were maintained at 37°C in a humidified atmosphere 
of 5% CO2 in air, detached with trypsin, resuspended in 
sterile saline, and subsequently implanted in the animals 
at the concentrations indicated above. Rats or mice 
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inoculated with vehicle (saline) served as controls (n= 6). 
In the AH130 experiment, animals were randomized and 
divided into four groups: controls (n= 6) and AH130 (n= 
8), administered or not VitD3. Treated groups received 
intragastrically a daily administration of 80 IU/kg body 
weight (b.w.) of VitD3 dissolved in 200 μl of corn oil. 
Control rats were administered with an even amount of 
corn oil. The same treatment schedule was also applied to 
a group of mice, divided into controls (C) and C26 hosts 
(C26), treated or untreated with VitD3. VitD3 dosage 
was selected on the basis of data reported in the literature 
as well as by performing dose-response preliminary 
experiments in control animals, having VDR as endpoint. 
The intragastrical route of administration was chosen 
taking into consideration a potential translation to the 
clinical practice.
Animal weight and food intake were recorded daily. 
AH130-bearing rats, C26 hosts and LLC-bearing mice 
were euthanized under anesthesia 7, 14 and 28 days after 
tumor transplantation, respectively. Several muscles and 
organs were rapidly excised, weighed, frozen in isopentane 
cooled with liquid N2, and stored at −80 °C.
In the regeneration experiment, skeletal muscle injury 
was induced in 8 week old mice by injecting 1.2% BaCl2 (30 
μl) into the left tibialis anterior muscle. The controlateral 
muscle was injected with PBS and used as control. Half of 
mice (n=6) received VitD as described above. After 15 days 
of recovery the animals were euthanized and the tibialis 
muscles were dissected and removed, rapidly frozen in 
melting isopentane and used for cross-sectional area (CSA) 
and protein expression analysis.
Healthy or arthritic male Wistar rats (150 g/6 weeks 
old) were purchased from Charles River. An intradermal 
injection of heat-inactivated Mycobacterium butyricum 
(4 mg) induced arthritis in the right paw of rats. Controls 
received just vehicle (paraffin oil, 100 μl). Animals were 
maintained on a regular dark-light cycle (light from 8 a.m. 
to 8 p.m.), with free access to food and water during the 
whole experimental period. Arthritic and control rats were 
divided into two groups: VitD treated (80 IU/kg b.w./day, 
intragastrical administration) or vehicle (corn oil) treated 
(sham). Body weight and arthritis severity were assessed 
daily. Evaluation of the latter was performed by measuring 
the arthritis index of each animal, which was scored by 
grading each paw from 0 to 4, since inflammation of the paw 
is associated with radiological and histological alterations 
of the joints ([53]). After 15 days, rats were sacrificed and 
muscles (gastrocnemius, tibialis anterior and heart), liver 
and spleen were rapidly excised, weighed, frozen in liquid 
nitrogen, and stored at –80°C for further analysis.
Human samples
Already available samples, deriving from a previous 
study [54], were used. Muscle biopsies were obtained 
from patients recruited at the M.G. Vannini Hospital 
in Rome (Italy) after signing an informed consent and 
after clearance by the local Ethical Committee. Briefly, 
patients undergoing abdominal surgery for cancer (mainly 
gastrointestinal tumors) or for non neoplastic reasons 
(used as controls) were included. The following exclusion 
criteria were adopted: liver failure, diabetes, metabolic 
acidosis, acute and chronic renal failure, sepsis, AIDS, 
inflammatory bowel diseases, acute and chronic hepatitis, 
autoimmune disorders and chronic obstructive pulmonary 
disease. Biopsy specimens were obtained during the initial 
phase of the operation from the rectus abdominis muscle 
(for details see [54]), immediately frozen in liquid nitrogen 
and stored at - 80 °C until analysis.
Vitamin D concentration
For the determination of VitD circulating levels, 
blood samples were centrifuged at 600g for 10 min 
and the separated plasma was stored at −20°C. 25D 
plasma levels were determined by radioimmunoassay 
(Immunodiagnostic Systems Holdings, Boldon, UK).
Histological analysis
Serial 10 μm-thick frozen sections were cut from 
cryopreserved tissue blocks, adhered to Superfrost Plus 
microscopy slides and stained with hematoxylin and eosin. 
All sections were examined by light microscopy (Nikon 
Eclipse TS100) and digital images were obtained with a 
Nikon COOLPIX 4500 camera. To assess myofiber CSA 
400 fibers of gastrocnemius muscle sections were counted 
and measured using Image J software (http://rsb.info.nih.
gov/ij/; NIH, Bethesda, MD).
Cell cultures
Murine C2C12 skeletal myoblasts (ATCC) were 
grown in high-glucose DMEM supplemented with 10% 
fetal bovine serum, 100 U/mL penicillin, 100 μg/mL 
streptomycin, 100 μg/mL sodium pyruvate, and 2 mmol/L 
l-glutamine and maintained at 37°C in a humidified 
atmosphere of 5% CO2 in air. Differentiation was 
induced by switching subconfluent cultures to DMEM 
supplemented with 2% horse serum (differentiation 
medium). In the differentiation experiments VitD 
(calcitriol; 1,25(OH)2 D dissolved in DMSO) was added 
to the medium at a final concentration of 10 nM or 100 
nM, starting from the first day of differentiation. Since 
VitD is known to have a short half life at 37°C (5/8 
hours), the medium was replaced every day during the 
experiments. Control cells received an equal amount of 
DMSO.
Gene silencing
VDR silencing was achieved by using shRNA. 
A set of four MISSION shRNAs targeting VDR mRNA 
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and cloned into plKO.1-puro expression vector was used. 
Third generation lentiviral particles (kindly provided by 
Prof. Ponzetto, CERMS - University of Torino, Torino, 
Italy) were used to deliver the shRNA to C2C12 cells. 
Cells were then incubated in their regular growth medium 
containing Puromycin 1μg/ml, in order to select for stably 
transformed cells. After testing the expression of VDR via 
western blotting analysis, cells infected with the shRNA 
providing the highest silencing were used for all the 
experiments (5’-CGGCCTGAGATCAATCACATTTAA
CTCGAGTTAAATGTGATTGATCTCAGGTTTTT-3’). 
Control cells were infected with a plKO.1-puro plasmid 
containing a non-specific shRNA (MISSION pLKO.1-
puro Non-Mammalian shRNA Control Plasmid DNA).
Western blotting analysis
Approximately 50 mg of gastrocnemius or tibialis 
muscle were homogenized in 80 mmol/L Tris-HCl, pH 
6.8, containing 100 mmol/L dithiothreitol, 70 mmol/L 
SDS, and 1 mmol/L glycerol, with freshly added protease 
and phosphatase inhibitor cocktails; kept on ice for 30 
minutes; centrifuged at 15,000 ×g for 10 minutes at 4°C 
and the supernatant collected. Protein concentration was 
assayed according to Bradford, using bovine serum albumin 
as working standard. C2C12 cells were lysed on RIPA 
buffer (50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 
1% Nonidet P-40, 0.25% sodium deoxycholate, 1 mmol/L 
phenylmethylsulfonyl fluoride) with freshly added protease 
and phosphatase inhibitor cocktails. Equal amounts of protein 
(30 μg) were heat-denaturated in sample-loading buffer (50 
mmol/L Tris-HCl, pH 6.8, 100 mmol/L dithiothreitol, 2% 
SDS, 0.1% bromophenol blue, 10% glycerol), resolved by 
SDS-PAGE, and transferred to nitrocellulose membranes 
(Bio-Rad Laboratories, Hercules, CA). The filters were 
blocked with Tris-buffered saline containing 0.05% Tween 
and 5% nonfat dry milk and then were incubated overnight 
with antibodies directed against VDR (mouse monoclonal 
antibody, clone D6, Santa Cruz Biotechnology, Santa Cruz, 
CA), Myogenin (mouse monoclonal antibody, clone F5D, 
Santa Cruz Biotechnology, Santa Cruz, CA), MyHC (mouse 
monoclonal antibody, clone MY32), Pax7 (Developmental 
Studies Hybridoma Bank, University of Iowa), MyoD (rabbit 
polyclonal antibody, clone M318, Santa Cruz Biotechnology, 
Santa Cruz, CA), GAPDH (goat polyclonal antibody, V18, 
Santa Cruz Biotechnology, Santa Cruz, CA) and tubulin 
(mouse monoclonal antibody, clone T5168). Peroxidase-
conjugated IgGs (Bio-Rad Laboratories) were used as 
secondary antibodies. Quantification of the bands was 
performed by densitometric analysis (TotalLab; Nonlinear 
Dynamics, Newcastle on Tyne, UK).
Real time PCR
Total RNA was obtained using TriPure isolation 
reagent (Roche Applied Science, Indianapolis, IN) 
following the manufacturer’s instructions. RNA 
concentration was determined fluorometrically using 
RiboGreen reagent (Invitrogen, Carlsbad, CA). RNA 
integrity was checked by electrophoresis on 1.2% agarose 
gel containing 0.02 mol/L morpholinopropanesulfonic 
acid and 18% formaldehyde. Total mRNA was 
retrotranscribed using an iScript cDNA synthesis kit (Bio-
Rad Laboratories). Transcript levels were determined by 
real-time PCR using the SsoFast EvaGreen supermix and 
the MiniOpticon thermal cycler (Bio-Rad Laboratories), 
normalizing the expression for TBP. Primer sequences 





Promoter analysis and chromatin 
immunoprecipitation assay (ChIP)
The promoter region (-6000bp, +500bp) of 
murine myogenin gene was analyzed for the presence 
of putative VDR binding sites (Matrix-Derived JASPAR 
CORE Models, Vertebrates, ID: MA0074.1) using the 
LASAGNA-Search web tool [55].
Chromatin was isolated from C2C12 myoblast 
untreated or treated during 4 hours with VitD in DMSO 
at a final concentration of 100 nM. ChIP was performed 
according to [56]. Cells were cross-linked adding to tissue 
culture medium PBS and 1% formaldehyde and incubating 
for 10 minutes. Crosslinking was blocked with 0.125 M 
glycine for 5 minutes. Cells were scraped and subsequently 
lysed in RIPA buffer (see above). Nuclei were pelleted by 
microcentrifugation and lysed by incubation in nuclear 
lysis buffer (1% sodium dodecyl sulfate, 10 mM EDTA, 50 
mM Tris-chloride pH 8.1, 0.5 mM phenylmethylsulfonyl 
fluoride, protease inhibitors). The resulting chromatin 
solution was sonicated to obtain fragments of 
approximately 0.5 kb and immunoprecipitated with 3.5 
µg of rabbit IgG or VDR (rabbit polyclonal antibody, 
clone C-20; Santa Cruz Biotechnology, Santa Cruz, 
CA). Immunoprecipitation procedures were performed 
according to [57]. Quantitative Real Time PCR was 
performed using SYBR green IQ reagent (Bio-Rad 
Laboratories) with CFX Connect detection system (Bio-






























C2C12 or primary cells were washed with PBS 
and fixed in 1:1 acetone:methanol. Samples were then 
probed with the following primary antibodies: MyHC 
(mouse monoclonal antibody, clone MY32), VDR (mouse 
monoclonal antibody, clone D6. Santa Cruz Biotechnology, 
Santa Cruz, CA), Myogenin (mouse monoclonal antibody, 
clone F5D. Santa Cruz Biotechnology, Santa Cruz, CA). 
Detection was performed using Alexa Fluor secondary 
antibodies (Life Technologies, Grand Island, NY). Nuclei 
were stained with DAPI fluorochrome, and the images 
were captured using an epi-illuminated fluorescence 
microscope (Axiovert 35; Carl Zeiss MicroImaging 
GmbH, Jena, Germany). About 200 myotubes/conditions 
were analyzed to assess the number of nuclei and myotube 
diameter.
Statistical analysis
All the results are expressed as means ± SD, except 
for Real Time PCR gene expression (means ± SEM). 
Representative Western blots show independent samples. 
The significance of the differences was evaluated by 
ANOVA followed by Tukey’s test.
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